IL-6 and Its Receptor Drive Opposite Effects on Survival, Large Genetic Study Finds

Inflammation sits at the intersection of nearly every major chronic disease, yet the causal story is tangled. Biomarkers that track inflammation are abundant in sick people, but tracking inflammation does not prove it. Disease itself causes inflammation, which means most observational studies cannot reliably tell us whether elevated inflammatory markers cause poor outcomes or merely accompany them.

Mendelian randomization offers a way around this problem. It uses inherited genetic variants - assigned at conception, before any disease develops - as instruments to test whether naturally higher lifelong levels of a given molecule actually cause the outcomes associated with it. A paper published in Aging-US applies this approach to IL-6 and its soluble receptor IL-6R, producing results with a striking asymmetry: one drives mortality up, the other drives it down.

The analysis and what it found

The study, led by Eliano P. Navarese from Link Campus University and Nicolaus Copernicus University, combined genome-wide association instruments derived from more than 750,000 individuals with mortality data from the FinnGen cohort, which tracked participants over a median follow-up of 11.7 years. The researchers assessed effects on all-cause mortality, atrial fibrillation, coronary artery disease, stroke, and lung cancer.

The results were directionally opposite for the two molecules. Genetically higher IL-6 levels were associated with increased all-cause mortality, with an odds ratio of 1.05 per one standard deviation increase (95% confidence interval: 1.02-1.08). Genetically higher IL-6 receptor levels showed the reverse: an odds ratio of 0.95 per standard deviation increase (95% CI: 0.91-0.98) for all-cause mortality, along with lower risks of atrial fibrillation, coronary artery disease, stroke, and lung cancer.

Two other inflammatory markers tested in the analysis - CRP and GDF15 - showed no significant causal effects on mortality. The researchers interpret this as evidence that these markers more likely reflect disease burden than actively drive it.

What this means biologically

The opposing directions for IL-6 and IL-6R are not paradoxical once the biology is unpacked. IL-6 is a pro-inflammatory cytokine that, at chronically elevated levels, promotes inflammatory states associated with atherosclerosis, plaque instability, and cardiovascular events. The soluble IL-6 receptor, by contrast, appears to modulate and dampen harmful IL-6 signaling at the vessel wall and heart muscle, producing a net protective effect on the cardiovascular system.

This interpretation aligns with clinical trial evidence for drugs that block IL-6R signaling, including tocilizumab and sarilumab, which have been tested and approved in inflammatory and autoimmune conditions. The genetic evidence now extends this picture toward cardiovascular prevention, suggesting that the same receptor antagonism that controls joint inflammation might also protect the heart.

"These results support IL-6R antagonism as a potential strategy for cardiovascular disease prevention," the authors write.

Limitations and next steps

The analysis was conducted exclusively in individuals of European ancestry, drawn primarily from FinnGen's Finnish cohort. Whether the same causal relationships hold in other genetic backgrounds is unknown and requires investigation. Genetic instruments can also be imperfect proxies for lifelong exposure to a molecule, and the effects estimated here reflect lifetime differences rather than the effects of starting or stopping a drug at a particular age.

Translating these genetic findings into prevention trials would require careful design. Primary prevention with an IL-6R antagonist - treating people who have not yet had a cardiovascular event - raises questions about which patients to target, what the long-term safety profile looks like in healthy populations, and whether the modest effect sizes seen in genetic data would translate into meaningful clinical benefits at an individual level. These are the standard gaps between genetic epidemiology and medical practice, and they are real.

The researchers call for mechanistic work mapping how IL-6 and IL-6R modulation alters vascular inflammation and downstream disease processes, alongside population trials designed specifically for primary prevention settings in high-risk groups. The genetic case for distinguishing between IL-6 and its receptor is now solid. What follows must be built on it carefully.